Abstract

Background: Nausea and vomiting are common side effects in parturients undergoing cesarean delivery performed under spinal anesthesia can be very unpleasant to the patients. The reported incidence of nausea and vomiting during cesarean performed under regional anesthesia varies from 50% to 80% when no prophylactic antiemetic is given. Therefore, use of prophylactic antiemetics in parturients undergoing cesarean delivery is recommended by some authors. Objective: In this study, alizapride was evaluated, as a D2 receptor antagonist, on the prevention of nausea and vomiting following Spinal Anesthesia in parturients undergoing elective cesarean section. Patients and Methods: The study was carried out in AL-Azhar University Hospitals, Obstetric and gynaecology department on 90 patients undergoing an elective, lower segment cesarean section (LSCS). All patients were identified by code number to maintain the privacy of the patients. Any unexpected risks appeared during the course of the research was cleared to the participants and the ethical committee on time. A written informed consent was obtained from all patients. Patients were divided into 3 groups, 30 patients for each group. Group I (Alizapride 50 group): Received intravenous (IV) Alizapride 50 mg diluted in 10 ml of normal saline over 1-5 minutes, immediately after clamping umbilical cord. Group II (Alizapride 100 group): Received intravenous (IV) Alizapride 100 mg diluted in 10 ml of normal saline over 1-5 minutes, immediately after clamping umbilical cord. Group III (Saline group): Received normal saline 10 ml, immediately after clamping umbilical cord.

Authors and Affiliations